Search clinical trials for: PRX-102 (pegunigalsidase alfa)

Total 186 results

Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Fabry Disease

United States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients (Bright51)

Fabry Disease

Belgium, United States, United Kingdom, Italy, Czechia, Denmark, Norway
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Fabry Disease

Australia, Netherlands, United Kingdom, Canada, Czechia, Norway, Slovenia
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Extension Study of PRX-102 for up to 60 Months

Fabry Disease

United States, Spain, United Kingdom, Paraguay
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)

Fabry Disease

United States, Netherlands, Hungary, United Kingdom, Czechia, Norway, Slovenia, Spain, Finland, France, Italy, Switzerland
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks (BRIGHT)

Fabry Disease

United States, Denmark, Belgium, United Kingdom, Norway, Italy, Czechia
Protalix

Withdrawn

Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease

Fabry Disease
Chiesi Farmaceutici S.p.A.
ICON plc

Not yet recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (FLY)

Fabry Disease
Chiesi Farmaceutici S.p.A.
ICON plc

Recruiting

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)

Fabry Disease

Japan
Westfälische Wilhelms-Universität Münster
Chiesi GmbH

Recruiting

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa (GoPEG)

Fabry Disease

Germany
Chiesi Farmaceutici S.p.A.
Chiesi USA, Inc.

Available

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Fabry Disease

United States
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Alexion Pharmaceuticals

Completed

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency (ARISE)

Lysosomal Acid Lipase Deficiency

France, Poland, United Kingdom, Spain, Mexico, Turkey, Japan, Australia, Russian Federation, United States, Germany, Italy, Czechia, Argentina, Croatia
Hoffmann-La Roche

Terminated

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE-OLE)

Idiopathic Pulmonary Fibrosis

United States, France, Israel, Spain, Belgium, Australia, Czechia, Denmark, Taiwan, Italy, Japan, Singapore, Turkey, Korea, Republic of, Germany, China, New Zealand, Argentina, Portugal, South Africa, Hungary, Canada, Poland, Greece, Ne... and more
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Fabry Disease

United States, Serbia, Spain, United Kingdom, Australia, Paraguay
Alexion Pharmaceuticals

Terminated

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

United Kingdom, Finland, United States, Italy
Alexion Pharmaceuticals

Completed

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Wolman Disease | Lysosomal Acid Lipase Deficiency

United Kingdom, France, United States, Egypt, Ireland
Alexion Pharmaceuticals

No longer available

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency
Protalix

Completed

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Gaucher Disease

Israel
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE)

Idiopathic Pulmonary Fibrosis

United States, Spain, France, Belgium, Australia, Denmark, Italy, Taiwan, Japan, Singapore, Turkey, Korea, Republic of, Germany, China, Ukraine, New Zealand, Netherlands, United Kingdom, Israel, Finland, Argentina, Czechia, Portugal, South... and more
Alexion Pharmaceuticals

Completed

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | LAL-Deficiency | Cholesterol Ester Storage Disease (CESD)

France, United Kingdom, United States, Canada, Czechia
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Protalix

Completed

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Gaucher Disease

Israel
Protalix

Completed

An Exploratory Phase 1 Microdose Study of PRX-105

Organophosphate Exposure

Israel
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
LENZ Therapeutics, Inc

Completed

Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Presbyopia

United States
Protalix

Unknown

Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Israel
Prof. Dr. Dieter Willbold
Medical University of Vienna; Alzheimer's Association; Helmholtz-Gemeinschaft... and other collaborators

Completed

MAD Phase I Study to Investigate Contraloid Acetate

Alzheimer Disease | Alzheimer Dementia

Germany
Protalex, Inc.

Completed

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (SPARTA)

Arthritis, Rheumatoid

United States
JW Pharmaceutical

Completed

A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.

Anemia of Chronic Kidney Disease

Korea, Republic of
Prof. Dr. Dieter Willbold
Medical University of Vienna; Helmholtz-Gemeinschaft Deutscher Forschungszentren... and other collaborators

Completed

SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate

Alzheimer Disease | Alzheimer Dementia

Germany
PRInnovation GmbH
Julius Clinical; Federal Agency for Disruptive Innovation - SPRIN-D; Priavoid

Recruiting

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease, Early Onset

Germany, Spain, Italy, Czechia, Netherlands, Poland
Protalex, Inc.

Completed

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

Healthy Volunteers

United States
Protalex, Inc.

Terminated

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Immune Thrombocytopenia

United States, United Kingdom
Protalex, Inc.

Terminated

PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP

Immune Thrombocytopenia

France, United Kingdom
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
QuatRx Pharmaceuticals Company

Completed

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Psoriasis

United States
Charite University, Berlin, Germany
Berlin Institute of Health; Federal Agency for Disruptive Innovation - SPRIN-D

Completed

Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

Germany
Provention Bio, Inc.

Completed

PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers (PROVENT)

Viral; Infection, Coxsackie(Virus)

Finland
Aravax Pty Ltd

Recruiting

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Immune System Diseases | Peanut Hypersensitivity | Peanut Allergy | Peanut-Induced Anaphylaxis

United States, Australia
Sykehuset Innlandet HF
Incen AG

Completed

Air Cleaners for Children and Adolescents With Asthma and Dog Allergy

Asthma | Allergy

Norway
Stuart Therapeutics, Inc.
ORA, Inc.

Completed

Study of ST-100 as Treatment for Dry Eye Disease

Dry Eye Disease

United States
Hospices Civils de Lyon
GlaxoSmithKline

Recruiting

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices (SECURE)

Asthma

France
NeuroRx, Inc.
Prevail Infoworks

Available

NRX-101 Expanded Access (NRX-101EAP)

Bipolar Depression | Bipolar Affective Disorder
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in an ADULT Workplace Environment

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Protalex, Inc.

Completed

6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection (SPARTA-II)

Arthritis, Rheumatoid

United States
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
Botanee Group Co., Ltd.

Active, not recruiting

A 28-day Clinical Study on Facial Skin Rejuvenation

Skin Manifestations | Wrinkle | Skin | Skin Laxity

China
Odyssey Group International, Inc.
Avance Clinical Pty Ltd.

Recruiting

A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers

Traumatic Brain Injury (TBI)

Australia
Aridis Pharmaceuticals, Inc.

Completed

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

Pseudomonas Aeruginosa Pneumonia

Belgium, United States, France, Spain, Georgia, Australia, Belarus, Czechia, Greece, Hungary, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Taiwan, Ukraine

Search clinical trials for: PRX-102 (pegunigalsidase alfa)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations